360 results on '"Shan, Jianqin"'
Search Results
2. Significance of Thrombocytopenia in Myelodysplastic Syndromes: Associations and Prognostic Implications
3. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy
4. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
5. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy
6. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase
7. Chromosomal abnormalities in Philadelphia chromosome–negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase
8. Predicting survival of patients with hypocellular myelodysplastic syndrome: Development of a disease-specific prognostic score system
9. Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy
10. Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib
11. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia
12. Prediction model for mortality after intracranial hemorrhage in patients with leukemia
13. Significance of Thrombocytopenia in Myelodysplastic Syndromes: Associations and Prognostic Implications
14. Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia
15. Imatinib Front-Line Therapy Is Safe and Effective in Patients With Chronic Myelogenous Leukemia With Pre-Existing Liver and/or Renal Dysfunction
16. Survival Outcomes for Clonal Evolution in Chronic Myeloid Leukemia Patients on Second Generation Tyrosine Kinase Inhibitor Therapy
17. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities
18. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: How does it relate to the original lenalidomide experience in MDS?
19. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase
20. Proposal for A New Risk Model in Myelodysplastic Syndrome That Accounts for Events Not Considered in the Original International Prognostic Scoring System
21. Cytogenetic and Molecular Responses and Outcome in Chronic Myelogenous Leukemia: Need for New Response Definitions?
22. Outcome of Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Post-Imatinib Mesylate Failure
23. Survival Advantage With Decitabine Versus Intensive Chemotherapy in Patients With Higher Risk Myelodysplastic Syndrome: Comparison with historical experience
24. Activity of Decitabine, A Hypomethylating Agent, in Chronic Myelomonocytic Leukemia
25. Update of the Decitabine Experience in Higher Risk Myelodysplastic Syndrome and Analysis of Prognostic Factors Associated With Outcome
26. Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse
27. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
28. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk of myelodysplastic syndrome: comparison with historical experience
29. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome:: Predictive prognostic models for outcome
30. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome
31. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome–positive chronic-phase chronic myeloid leukemia after failure of interferon-α
32. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy
33. Outcome of Patients with Acute Myelogenous Leukemia after Second Salvage Therapy
34. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia—Comparison with historic experience
35. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia
36. Imatinib mesylate therapy improves survival in patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase
37. Results of triple therapy with interferon-alpha, cytarabine, and hemoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase
38. Results of decitabine (5-Aza-2'Deoxycutidine) therapy in 130 patients with chronic myelogenous leukemia
39. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy
40. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia
41. Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase
42. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia
43. Imatinib mesylate (STI571) therapy for Philadelphia chromosome–positive chronic myelogenous leukemia in blast phase
44. Phase 1 study of polyethylene glycol formulation of interferon α-2B (Schering 54031) in Philadelphia chromosome–positive chronic myelogenous leukemia
45. A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia
46. Predictors of Outcome In Adult Patients with Acute Myeloid Leukemia In First Relapse,
47. Very Long-Term Follow-up Results of Imatinib Mesylate Therapy in Chronic Phase Chronic Myeloid Leukemia After Failure of Interferon Alpha Therapy
48. Detection of Minimal Residual Leukemia Predicts the Outcome of Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors Plus Chemotherapy
49. Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?
50. Association of Comorbidities With Overall Survival in Myelodysplastic Syndrome: Development of a Prognostic Model
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.